HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Inclusion Criteria:

• locally advanced or metastatic pancreatic cancer precluding curative surgical resection and recurrent pancreatic cancer
• Measurable disease by CT scan
• ECOG performance status 0-2
• Life expectancy > 3 months
• laboratory values as follows: 2,000/mm3 < WBC < 15,000/mm3, Platelet count >75,000/mm3, Total Bilirubin <1.5 mg/dl, Asparate transaminase <150IU/L, Alanine transaminase < 150 IU/L, Creatinine < 3.0mg/dl
• HLA-A*0201
• Able and willing to give valid written infromed consent

Exclusion Criteria:

• Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception)
• Breast-feeder
• Active or uncontrolled infection
• Prior chemotherapy, radiation therapy, or immunotherapy within 4 weeks
• Serious or uncured wound
• Active or uncontrolled other malignancy
• Steroids or immunosuppressing agent dependent status
• Interstitial pneumonia
• Ileus
• Decision of unsuitableness by principal investigator or physician-in-charge